Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04661852
Title Cabozantinib With Topotecan-Cyclophosphamide
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

osteosarcoma

neuroectodermal tumor

Ewing sarcoma

Therapies

Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan

Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.